181 related articles for article (PubMed ID: 19887050)
21. Essential role for T cells in human B-cell lymphoproliferative disease development in severe combined immunodeficient mice.
Johannessen I; Asghar M; Crawford DH
Br J Haematol; 2000 Jun; 109(3):600-10. PubMed ID: 10886210
[TBL] [Abstract][Full Text] [Related]
22. Increased T-cell activation and Th1 cytokine concentrations prior to the diagnosis of B-cell lymphoma in HIV infected patients.
Ouedraogo DE; Makinson A; Kuster N; Nagot N; Rubbo PA; Bollore K; Foulongne V; Cartron G; Olive D; Reynes J; Vendrell JP; Tuaillon E
J Clin Immunol; 2013 Jan; 33(1):22-9. PubMed ID: 22914896
[TBL] [Abstract][Full Text] [Related]
23. Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors.
Eom HS; Choi BK; Lee Y; Lee H; Yun T; Kim YH; Lee JJ; Kwon BS
J Immunother; 2016 Apr; 39(3):140-8. PubMed ID: 26938947
[TBL] [Abstract][Full Text] [Related]
24. Adoptive transfer of diabetes into immunodeficient NOD-scid/scid mice. Relative contributions of CD4+ and CD8+ T-cells from diabetic versus prediabetic NOD.NON-Thy-1a donors.
Christianson SW; Shultz LD; Leiter EH
Diabetes; 1993 Jan; 42(1):44-55. PubMed ID: 8093606
[TBL] [Abstract][Full Text] [Related]
25. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
[TBL] [Abstract][Full Text] [Related]
26. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes.
Margalit M; Shibolet O; Klein A; Elinav E; Alper R; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2005 Jun; 115(3):443-9. PubMed ID: 15688366
[TBL] [Abstract][Full Text] [Related]
27. NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma.
Mattarollo SR; West AC; Steegh K; Duret H; Paget C; Martin B; Matthews GM; Shortt J; Chesi M; Bergsagel PL; Bots M; Zuber J; Lowe SW; Johnstone RW; Smyth MJ
Blood; 2012 Oct; 120(15):3019-29. PubMed ID: 22932803
[TBL] [Abstract][Full Text] [Related]
28. Primary nasopharyngeal non-Hodgkin lymphoma and its relationship with Epstein-Barr virus infection.
Zhang B; Zong Y; He J; Zhong B; Lin S
Chin Med J (Engl); 2003 Jun; 116(6):913-7. PubMed ID: 12877806
[TBL] [Abstract][Full Text] [Related]
29. Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies.
Davis JE; Moss DJ
Tissue Antigens; 2004 Apr; 63(4):285-92. PubMed ID: 15009802
[TBL] [Abstract][Full Text] [Related]
30. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
31. Adoptive transfer of ex vivo immune-programmed NKT lymphocytes alleviates immune-mediated colitis.
Shibolet O; Kalish Y; Klein A; Alper R; Zolotarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
J Leukoc Biol; 2004 Jan; 75(1):76-86. PubMed ID: 14557387
[TBL] [Abstract][Full Text] [Related]
32. Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma.
Fogg MH; Wirth LJ; Posner M; Wang F
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3318-23. PubMed ID: 19211798
[TBL] [Abstract][Full Text] [Related]
33. Dendritic cells activated by an anti-inflammatory agent induce CD4(+) T helper type 2 responses without impairing CD8(+) memory and effector cytotoxic T-lymphocyte responses.
Wang Y; Da'Dara AA; Thomas PG; Harn DA
Immunology; 2010 Mar; 129(3):406-17. PubMed ID: 19922421
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma.
Duraiswamy J; Sherritt M; Thomson S; Tellam J; Cooper L; Connolly G; Bharadwaj M; Khanna R
Blood; 2003 Apr; 101(8):3150-6. PubMed ID: 12468425
[TBL] [Abstract][Full Text] [Related]
35. Glucose-regulated protein 94/glycoprotein 96 elicits bystander activation of CD4+ T cell Th1 cytokine production in vivo.
Baker-LePain JC; Sarzotti M; Nicchitta CV
J Immunol; 2004 Apr; 172(7):4195-203. PubMed ID: 15034032
[TBL] [Abstract][Full Text] [Related]
36. Invariant NKT cells regulate experimental autoimmune uveitis through inhibition of Th17 differentiation.
Oh K; Byoun OJ; Ham DI; Kim YS; Lee DS
Eur J Immunol; 2011 Feb; 41(2):392-402. PubMed ID: 21268009
[TBL] [Abstract][Full Text] [Related]
37. ZBTB7B (Th-POK) regulates the development of IL-17-producing CD1d-restricted mouse NKT cells.
Enders A; Stankovic S; Teh C; Uldrich AP; Yabas M; Juelich T; Altin JA; Frankenreiter S; Bergmann H; Roots CM; Kyparissoudis K; Goodnow CC; Godfrey DI
J Immunol; 2012 Dec; 189(11):5240-9. PubMed ID: 23105140
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of variations in levels of Epstein-Barr Virus (EBV) antigen and adaptive immune response during chronic active EBV infection in children.
Xing Y; Song HM; Wei M; Liu Y; Zhang YH; Gao L
J Immunotoxicol; 2013; 10(4):387-92. PubMed ID: 23418935
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
40. Human natural killer T cells are heterogeneous in their capacity to reprogram their effector functions.
Eger KA; Sundrud MS; Motsinger AA; Tseng M; Van Kaer L; Unutmaz D
PLoS One; 2006 Dec; 1(1):e50. PubMed ID: 17183680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
